Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.

We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.

If you need assistance finding or assessing business development and/or partnership opportunities, contact us at

Current Projects

China: Opportunities to Access Partnerships and Capital  
Posted on Feb 14, 2015


Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? Through our local partners in China, we can help you navigate this rapidly growing, but complex market. Indeed, China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming –

  Read More»

Seeking Parenteral & Ophthalmic Products for In-Licensing  
Posted on Jan 21, 2016


Lacerta Bio is seeking both parenteral and ophthalmic (topical) products for in-licensing on behalf of a US-based client.  Key criteria are: > Products which can be developed via the 505(b)(2) regulatory process in the US > No specific therapeutic area or indication > Injectable could be infusion, prefilled syringe, or related presentation > Ophthalmics are

  Read More»

Novel Anti-Bacterials Available For Licensing  
Posted on Oct 04, 2016


  Lacerta Bio is pleased to present two novel antibiotics with excellent properties on behalf of our client. The first is a peptide antibiotic which inhibits cell wall synthesis, making it suitable for the intravenous treatment of troublesome Gram Positive bacteria, such as MRSA, VRE, and many other resistant pathogens. The second is a liposlycodepsipeptide suitable

  Read More»

Our Latest Article

Thoughts Leading Up To #BIO2017 
Posted on Jun 15, 2017



#BIO2017 is days away. What can we expect?


Crowded Partnering – By our unofficial count, the number of companies registered for One-on-One Partnering exceeds the number from San Francisco last year.

While having more Exhibitors is nice, more people and companies in Partnering means more opportunities to in- or out-license, find new clients, new partners, and build new career and personal friendships.

There will be moments when the hallways will be impassable due to the crowds…which is great! 

Reading Between The Lines – The reporting during and after the convention will be about the usual things, like the biggest deals or the latest clinical success (or failure).

The reality is that there is a lot more activity which takes place that is never reported or publicized.

Deals which do not “move the needle” today (an admittedly awful term) can become headlines in a few years.

So it’s important to chat, listen, and follow non-MSM sources of information. 

Some Will, Some Won’t – At BIO and other conferences, you will meet some of the smartest, nicest people in our industry.

And then there are those who are unfriendly, scowling, unhappy people who have no interest in being there, no interest in interacting, and are just plain miserable to be with.

I concede that some of these folks have personal problems which are front of mind. But there are those who are simply like this all the time, especially when they travel.

If you are one of these people, please try to remember that you are at BIO first and foremost to build and develop relationships.

Why scowl at me when I could have the solution to your business problem?

So smile, shake hands, and let’s talk. 

Follow the action on Twitter via #BIO2017.

Latest Posts

What is your Acceptance Rate? 
Posted on Jun 02, 2017

  An Acceptance Rate is simply the percentage of meeting requests which are accepted at a given conference. At Lacerta Bio, we have been tracking Acceptance Rates for conferences since 2011. We track it for every conference at the corporate level, and also at the client level. But why bother? Daily Planning – Using historical

NSAIDs: More Bad News 
Posted on May 15, 2017

  NSAIDs are an $11-12+ billion market, yet the problems with these drugs continue to make headlines.  The most recent study examined data from nearly 450,000 patients, and concluded (our emphasis):  All NSAIDs, including naproxen, were found to be associated with an increased risk of acute myocardial infarction. Risk of myocardial infarction with celecoxib was

Control or Collaboration – Value Creation & Success Focus 
Posted on May 12, 2017

  The following commentary is from Mr. Tom Brya, Managing Director at Titenare GXL. Titenare is an international consultancy providing integrated, knowledge-based services and  solutions to pharma companies internationally. For further information, please visit The pharma business model is rapidly moving towards a PwC 2009 prediction, which said that the industry will become collaboration-centric. This was

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.